A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2013 Actual initiation date changed from Feb 2013 to May 2013 as reported by ClinicalTrials.gov.
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.